Company / Capital Expenditures
Moderna Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$192.0M
FY2025
5-year range
$32.0M / $1.1B
FY2021-FY2025
Trend
-81.7%
vs FY2024
Sector context
#16 of 194
Health Care
What the data says
Among 194 Health Care companies, Moderna is in the top 8% for capital expenditures. Capital Expenditures has fluctuated over the past 10 years, ranging from $32M in FY2021 to $1.1B in FY2024.
Based on SEC 10-K filings.
$192M in FY2025 with a 5-year CAGR of +23.1%. Top quartile in the Health Care sector.
Declined from $707M to $192M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +41.3%
- 5-Year CAGR
- +23.1%
- 10-Year CAGR
- -
Sector benchmark
Top 8% in Health CareTop 8% of 194This company $192.0M Sector average $117.5M
▼
+63.4% above sector average
Key checks
Key Insights
- 5-year CAGR of +23.1%, indicating consistent growth.
- In FY2025, capital expenditures decreased 81.7% year-over-year.
- Ranks #16 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 1.13 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $192.0M | -81.7% |
| FY2024 | $1.1B | +48.7% |
| FY2023 | $707.0M | +939.7% |
| FY2022 | $68.0M | +112.5% |
| FY2021 | $32.0M | -52.9% |
| FY2020 | $68.0M | +112.5% |
| FY2019 | $32.0M | -69.7% |
| FY2018 | $105.8M | +81.1% |
| FY2017 | $58.4M | +76.2% |
| FY2016 | $33.1M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026